Can’t Get No Satisfaction? Will Pay for Performance Help?
暂无分享,去创建一个
[1] B. O'brien,et al. Building uncertainty into cost-effectiveness rankings: portfolio risk-return tradeoffs and implications for decision rules. , 2000, Medical care.
[2] Yoav Ben-Shlomo,et al. Multiple sclerosis risk sharing scheme: two year results of clinical cohort study with historical comparator , 2009, BMJ : British Medical Journal.
[3] B. O'brien,et al. Analysis of a pharmaceutical risk sharing agreement based on the purchaser's total budget. , 2005, Health economics.
[4] L. Garrison,et al. Paying for Outcomes: Innovative Coverage and Reimbursement Schemes for Pharmaceuticals , 2009, Journal of managed care pharmacy : JMCP.
[5] Amiram Gafni,et al. Optimizing a portfolio of health care programs in the presence of uncertainty and constrained resources. , 2003, Social science & medicine.
[6] David Zilberman,et al. Demonstrations and money-back guarantees: market mechanisms to reduce uncertainty , 2001 .
[7] Stephen Chapman,et al. Setting up an outcomes guarantee for pharmaceuticals: new approach to risk sharing in primary care , 2003, BMJ : British Medical Journal.
[8] D. Chadwick,et al. Shared scheme for assessing drugs for multiple sclerosis :Dealing with uncertainties about cost effectiveness of treatments is difficult problem , 2003, BMJ : British Medical Journal.
[9] Amiram Gafni,et al. Economics and the evaluation of health care programmes: generalisability of methods and implications for generalisability of results. , 2003, Health policy.
[10] K. Arrow,et al. Uncertainty and the Evaluation of Public Investment Decisions , 2014 .
[11] Andrew R Willan,et al. Expected value of information and decision making in HTA. , 2007, Health economics.
[12] S. Palmer,et al. Incorporating option values into the economic evaluation of health care technologies. , 2000, Journal of health economics.
[13] R. Weintraub,et al. Public Funding of Bosentan for the Treatment of Pulmonary Artery Hypertension in Australia , 2012, PharmacoEconomics.
[14] David Zilberman,et al. Valuation and management of money-back guarantee options , 2002 .
[15] No cure, no pay , 2005, BMJ : British Medical Journal.
[16] J. Vernon,et al. Pharmaceutical Risk-Sharing Agreements , 2012, PharmacoEconomics.
[17] G. Pouvourville. Risk-sharing agreements for innovative drugs , 2006, The European Journal of Health Economics.
[18] A H Briggs,et al. Affordability and cost-effectiveness: decision-making on the cost-effectiveness plane. , 2001, Health economics.
[19] A Gafni,et al. Guidelines for the adoption of new technologies: a prescription for uncontrolled growth in expenditures and how to avoid the problem. , 1993, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[20] L. Garrison,et al. The drug budget silo mentality in Europe: an overview. , 2003, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[21] Andrew R Willan,et al. Globally optimal trial design for local decision making. , 2009, Health economics.